|
Beijing Aosaikang Pharmaceutical Co. ، Ltd. (002755.SZ) تقييم DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHZ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) Bundle
Optimize your time and improve precision with our (002755SZ) DCF Calculator! Equipped with real Beijing Aosaikang Pharmaceutical Co., Ltd. data and customizable assumptions, this tool enables you to forecast, analyze, and assess (002755SZ) as if you were a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,518.6 | 3,782.7 | 3,106.7 | 1,872.6 | 1,443.5 | 1,094.1 | 829.4 | 628.7 | 476.5 | 361.2 |
| Revenue Growth, % | 0 | -16.29 | -17.87 | -39.72 | -22.92 | -24.2 | -24.2 | -24.2 | -24.2 | -24.2 |
| EBITDA | 977.1 | 913.7 | 498.4 | -163.6 | -112.7 | 99.1 | 75.1 | 56.9 | 43.1 | 32.7 |
| EBITDA, % | 21.62 | 24.15 | 16.04 | -8.73 | -7.81 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 |
| Depreciation | 88.8 | 94.6 | 98.5 | 97.9 | 87.4 | 41.4 | 31.4 | 23.8 | 18.0 | 13.7 |
| Depreciation, % | 1.97 | 2.5 | 3.17 | 5.23 | 6.06 | 3.78 | 3.78 | 3.78 | 3.78 | 3.78 |
| EBIT | 888.3 | 819.1 | 399.9 | -261.4 | -200.2 | 57.7 | 43.7 | 33.1 | 25.1 | 19.0 |
| EBIT, % | 19.66 | 21.65 | 12.87 | -13.96 | -13.87 | 5.27 | 5.27 | 5.27 | 5.27 | 5.27 |
| Total Cash | 1,287.1 | 1,469.1 | 1,688.0 | 1,611.8 | 1,760.9 | 673.4 | 510.4 | 386.9 | 293.3 | 222.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,052.2 | 997.5 | 581.9 | 323.0 | 181.2 | 214.9 | 162.9 | 123.5 | 93.6 | 70.9 |
| Account Receivables, % | 23.29 | 26.37 | 18.73 | 17.25 | 12.56 | 19.64 | 19.64 | 19.64 | 19.64 | 19.64 |
| Inventories | 226.6 | 168.7 | 141.8 | 141.5 | 167.5 | 72.7 | 55.1 | 41.7 | 31.6 | 24.0 |
| Inventories, % | 5.01 | 4.46 | 4.57 | 7.56 | 11.6 | 6.64 | 6.64 | 6.64 | 6.64 | 6.64 |
| Accounts Payable | 275.4 | 95.3 | 65.7 | 39.1 | 38.3 | 33.9 | 25.7 | 19.4 | 14.7 | 11.2 |
| Accounts Payable, % | 6.09 | 2.52 | 2.12 | 2.09 | 2.65 | 3.09 | 3.09 | 3.09 | 3.09 | 3.09 |
| Capital Expenditure | -169.0 | -199.7 | -133.8 | -150.5 | -129.3 | -66.3 | -50.3 | -38.1 | -28.9 | -21.9 |
| Capital Expenditure, % | -3.74 | -5.28 | -4.31 | -8.03 | -8.96 | -6.06 | -6.06 | -6.06 | -6.06 | -6.06 |
| Tax Rate, % | 26.08 | 26.08 | 26.08 | 26.08 | 26.08 | 26.08 | 26.08 | 26.08 | 26.08 | 26.08 |
| EBITAT | 781.3 | 719.8 | 374.1 | -265.1 | -148.0 | 51.1 | 38.8 | 29.4 | 22.3 | 16.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -302.3 | 547.1 | 751.8 | -85.2 | -74.8 | 82.9 | 81.2 | 61.6 | 46.7 | 35.4 |
| WACC, % | 5.91 | 5.91 | 5.91 | 5.91 | 5.9 | 5.91 | 5.91 | 5.91 | 5.91 | 5.91 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 266.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 36 | |||||||||
| Terminal Value | 924 | |||||||||
| Present Terminal Value | 693 | |||||||||
| Enterprise Value | 960 | |||||||||
| Net Debt | -923 | |||||||||
| Equity Value | 1,883 | |||||||||
| Diluted Shares Outstanding, MM | 928 | |||||||||
| Equity Value Per Share | 2.03 |
What You Will Receive
- Authentic 002755SZ Financial Data: Pre-loaded with Beijing Aosaikang Pharmaceutical's historical and projected metrics for accurate analysis.
- Fully Customizable Template: Easily adjust essential inputs such as revenue growth, WACC, and EBITDA percentage.
- Instant Calculations: Witness real-time updates of Beijing Aosaikang's intrinsic value as you make changes.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF outcomes.
- User-Friendly Interface: Streamlined layout with clear guidelines suitable for all skill levels.
Key Features
- 🔍 Real-Life Aosaikang Pharmaceutical Financials: Pre-filled historical and projected data for Beijing Aosaikang Pharmaceutical Co., Ltd. (002755SZ).
- ✏️ Fully Customizable Inputs: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas calculate the intrinsic value of Aosaikang Pharmaceutical using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Aosaikang Pharmaceutical’s valuation immediately after making adjustments.
- Scenario Analysis: Evaluate and compare outcomes for different financial assumptions side-by-side.
How It Works
- Download: Obtain the pre-configured Excel file containing Beijing Aosaikang Pharmaceutical Co., Ltd.'s (002755SZ) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and evaluate different outcomes instantly.
- Make Decisions: Leverage the valuation insights to inform your investment strategies.
Why Choose This Calculator for Beijing Aosaikang Pharmaceutical Co., Ltd. (002755SZ)?
- All-in-One Solution: Features DCF, WACC, and financial ratio assessments seamlessly integrated.
- Personalized Inputs: Modify the yellow-highlighted fields to explore different investment scenarios.
- In-Depth Analysis: Automatically computes the intrinsic value and Net Present Value for Beijing Aosaikang Pharmaceutical Co., Ltd. (002755SZ).
- Ready-to-Use Data: Comes with historical and projected data to provide reliable starting points.
- Expert-Level Accuracy: Perfect for financial analysts, investors, and business consultants working with Beijing Aosaikang Pharmaceutical Co., Ltd. (002755SZ).
Who Should Use This Product?
- Investors: Effectively assess the fair value of Beijing Aosaikang Pharmaceutical Co., Ltd. (002755SZ) before making investment choices.
- CFOs: Utilize a professional-grade DCF model for precise financial reporting and analysis.
- Consultants: Easily customize the template for client valuation reports.
- Entrepreneurs: Acquire valuable insights into financial modeling practices employed by leading pharmaceutical companies.
- Educators: Implement it as a resource for teaching valuation techniques and methodologies.
Contents of the Template
- Pre-Filled Data: Contains historical financials and forecasts for Beijing Aosaikang Pharmaceutical Co., Ltd. (002755SZ).
- Discounted Cash Flow Model: An editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A specific sheet designed for calculating WACC using tailored inputs.
- Key Financial Ratios: Evaluate Beijing Aosaikang's profitability, efficiency, and financial leverage.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables that summarize essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.